EXPERIENCE OF USE OF BLEMAREN® IN THE TREATMENT OF PATIENTS IN URIC ACID AND CALCIUM OXALATE UROLITHIASIS
- Authors: Konstantinova O.V1, Yanenko E.K1
-
Affiliations:
- SRI of Urology and Interventional Radiology n.a. N.A. Lopatkin -Branch of the FSBI «National Medical Research Center of Radiology» of RMPH
- Issue: No 5 (2015)
- Pages: 22-26
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/282226
- ID: 282226
Cite item
Open Access
Access granted
Abstract
154 patients with urolithiasis were under outpatient observation for 2-8 years. Among them there were 76 women and 78 men aged 21-66 years, of which 46 patients with uric acid urolithiasis, and 88 - with calcium oxalate urolithiasis. Treatment of patients was carried out systematically, depending on their condition. Indications for the application of Blemaren® included the presence of uric acid stones, uric acid and/or oxalate crystalluria. The duration of treatment was 6.1 months. The dosage of the drug varied from 6 to 18 g per day and was selected individually, depending on the purpose of the appointment of Blemaren®. Reduction of the urine pH to 6.2- 6.8-7.2 was the criterion for properly selected dose. To dissolve uric acid stones in the presence of hyperuricemia and/or hyperuricuria, Blemaren ® was administered in combination with allopurinolata dose of 0.1 g 3-4 times a day. Besides pharmacotherapy, treatment included diet therapy. It was found that the morning urine pH in urate urolithiasis is sustainable and has a range of 5.0-6.0, in 80.4% of cases - range of 5.0-5.5. In calcium oxalate urolithiasis this parameter is also stable and has a range of 5.0-6.7, in 82.9% of cases - range of 5.5-6.0. Optimal urine pH to eliminate uric acid and oxalate crystalluria in patients with uric acid and calcium oxalate urolithiasis is the interval of 6.2-6.4. It was shown that Blemaren® is a highly effective agent for treatment and prevention of uric acid and calcium oxalate crystalluria in calcium oxalate and uric acid urolithiasis. Further, its effectiveness in dissolving of uric acid stones in the absence of an infectious inflammatory process is 82.3%.
Full Text
About the authors
O. V Konstantinova
SRI of Urology and Interventional Radiology n.a. N.A. Lopatkin -Branch of the FSBI «National Medical Research Center of Radiology» of RMPH
Email: konstant-ov@yandex.ru
Doctor of Medical Sciences, Chief Researcher at the Division of Urolithiasis
E. K Yanenko
SRI of Urology and Interventional Radiology n.a. N.A. Lopatkin -Branch of the FSBI «National Medical Research Center of Radiology» of RMPH
References
- Prien E.L. Studies in urolithiasis: III Physico-chemical principles in stone formation and prevention. J Urol. 1955;73:627.
- Coe F.L. Nephrolithiasis pathogenesis and treatment. Year Book medical Publishers. Chicago-London, 1978.
- Ewans R.A., Maher P.O., AgostinoM., Wong S.Y., Marel G.M., Hills E. Investigation and treatment of renal calculi. Med. J. Austr. 1985;143(7):278-281.
- Чудновская М.В., Даренков А.Ф., Яненко Э.К. и соавт. Методические рекомендации. Схемы лечения и профилактики мочекислого, кальций-оксалатного и кальций-фосфатного уролитиаза. М., 1992, 12 с.
- Пытель Ю.А., Золотарев И.И. Уратный нефролитиаз. М., Медицина, 1995, 176 с.
- Rodman J.S. Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology. 2002;60:378.
- Колпаков И.С. Мочекаменная болезнь. Пособие для врачей. М., 2006, 21 с.
- Клименко П.М., Чабанов В.А., Акиншевич И.Ю. Возможности консервативного лечения больных уратным нефролитиазом. Новости медицины и фармации. 2010;3:5-7.
- Глыбочко П.В., Аляев Ю.Г., Рапопорт Л.М., Цариченко Д.Г., Фролова Е.А. Современная консервативная (цитратная) терапия при уратных камнях мочеточников. Урология. 2014;5:10-13.
- Eisner B.H., Goldfarb D.S., Pareek G. Pharmacologic treatment of kidney stone disease. Urol Clin North Am. 2013;40(1):21-30.
- Preminger G.M., Sakhaee K., Pak C.Y. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol. 1988;139:240.
- Ryall R.L. Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol. 1997;15:155.
- Zuckerman J.M., Assimos D.G. Hypocitraturia: pathophysiology and medical management. Rev Urol. 2009;11:134.
- Preminger G.M., Sakhaee K., Skurla C., Pak C.Y. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 1985;134:20.
- Türk C., Knoll T., Petrik A., Sarica K., Skolarikos A., Straub M., Seitz C. Guidelines on Urolithiasis. European Association of Urology 2015.
- Trinchieri A. Epidemiology of urolithiasis: an update. Clin Cases Miner Bone Metab. 2008;5(2):101-06.
- Yasui T., Ando R., Okada A., Tozawa K., Iguchi M., Kohri K. Epidemiology of urolithiasis for improving clinical practic. Hinyokika Kiyo. 2012;58(12):697-701.
- Аполихин О.И., Сивков А.В., Москалева Н.Г., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за десятилетний период (2002-2012 гг.) по данным официальной статистики. Экспериментальная и клиническая урология. 2014;2:2-12.
Supplementary files
